Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has received an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $18.89.

TEVA has been the subject of several recent analyst reports. Barclays raised their price objective on shares of Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research report on Wednesday, July 10th. UBS Group increased their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Jefferies Financial Group lifted their target price on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Finally, StockNews.com cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Thursday.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, insider Eric A. Hughes sold 24,537 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total value of $423,263.25. Following the completion of the transaction, the insider now owns 45,060 shares of the company’s stock, valued at approximately $777,285. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.55% of the stock is currently owned by corporate insiders.

Institutional Trading of Teva Pharmaceutical Industries

Hedge funds have recently modified their holdings of the stock. Centaurus Financial Inc. purchased a new stake in Teva Pharmaceutical Industries during the 2nd quarter worth about $228,000. Sanctuary Advisors LLC acquired a new stake in Teva Pharmaceutical Industries in the second quarter valued at approximately $560,000. Cetera Investment Advisers lifted its stake in Teva Pharmaceutical Industries by 83.9% in the second quarter. Cetera Investment Advisers now owns 60,868 shares of the company’s stock worth $989,000 after acquiring an additional 27,765 shares during the last quarter. Truist Financial Corp grew its holdings in Teva Pharmaceutical Industries by 7.0% during the 2nd quarter. Truist Financial Corp now owns 3,885,251 shares of the company’s stock worth $63,135,000 after acquiring an additional 254,483 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its position in shares of Teva Pharmaceutical Industries by 38.0% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,319,217 shares of the company’s stock valued at $21,437,000 after purchasing an additional 363,217 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Up 0.6 %

TEVA stock opened at $17.48 on Friday. The company has a market cap of $19.80 billion, a price-to-earnings ratio of -42.63, a PEG ratio of 1.21 and a beta of 0.88. The firm has a 50-day moving average of $17.83 and a two-hundred day moving average of $16.35. Teva Pharmaceutical Industries has a 12 month low of $8.06 and a 12 month high of $19.08. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.52.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.03. The firm had revenue of $4.16 billion for the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. As a group, analysts forecast that Teva Pharmaceutical Industries will post 2.33 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.